NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial
I'm LongbridgeAI, I can summarize articles.NeuroSense Therapeutics reported positive Phase 2 biomarker signals for PrimeC in an Alzheimer’s trial, showing changes in tau, amyloid-beta, and inflammatory markers. These results support plans for a larger clinical study. However, analyst sentiment is mixed; while one rating is 'Buy' with a $9 target, TipRanks’ AI assigns a 'Neutral' due to weak financials, including no revenue and significant losses.
The latest announcement is out from Neurosense Therapeutics Ltd. ( (NRSN) ).
On June 25, 2026, NeuroSense Therapeutics reported positive biomarker data from its Phase 2 RoAD proof-of-concept trial of PrimeC in Alzheimer’s disease, a randomized, double-blind, placebo-controlled study involving eight participants. Plasma analyses in three patients who completed 12 months of follow-up showed changes in hallmark Alzheimer’s biomarkers, including brain-derived tau, phospho-tau and the amyloid-beta 42/40 ratio, as well as in misfolded proteins alpha-synuclein and TDP-43 that commonly co-occur with Alzheimer’s pathology.
Additional shifts were observed in biomarkers of oxidative stress and inflammation, with all findings directionally aligned with PrimeC’s proposed multi-target mechanism and consistent with effects seen in NeuroSense’s ALS program, reinforcing evidence of shared neurodegenerative pathways. These biomarker results, together with previously reported favorable safety and tolerability and the absence of serious adverse events in RoAD, underpin NeuroSense’s plan to design a larger, adequately powered clinical study in Alzheimer’s disease, potentially strengthening its position in the competitive neurodegeneration drug-development landscape.
The most recent analyst rating on (NRSN) stock is a Buy
with a $9.00 price target.
To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock,
see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Neutral.
The score is primarily weighed down by weak financial performance (no revenue, significant ongoing losses, negative free cash flow, and negative equity/declining assets). Technicals are mixed with longer-term downtrend signals, and valuation is not supportive due to negative earnings and no dividend.
To see Spark’s full report on NRSN stock,
click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a late-stage clinical biotechnology company focused on developing combination therapies for severe neurodegenerative diseases, including amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease. Its lead candidate, PrimeC, is an extended-release oral formulation combining ciprofloxacin and celecoxib to target multiple pathways implicated in neurodegeneration, such as neuron degeneration, inflammation, iron accumulation and impaired RNA regulation.
The company’s strategy centers on multi-target approaches informed by extensive biomarker research, aiming to address the complexity and unmet medical need in neurodegenerative disorders where existing treatments offer only limited symptomatic relief. NeuroSense is listed on Nasdaq and operates from Herzliya, Israel, with programs advancing through late-stage clinical development.
Average Trading Volume: 138,597
Technical Sentiment Signal: Sell
Current Market Cap: $27.14M